Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O9DK
|
|||
| Former ID |
DIB010497
|
|||
| Drug Name |
PF-05280586
|
|||
| Indication | Cluster headache [ICD-11: 8A81.0; ICD-10: G44.0] | Phase 3 | [1] | |
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 3 | [2] | ||
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Antagonist | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02213263) A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.